• Molecular NameAmbenonium
  • SynonymAmbenonum
  • Weight537.576
  • Drugbank_IDDB01122
  • ACS_NO7648-98-8
  • Show 3D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)-3.22
  • pkaN/A
  • LogD (pH=7, predicted)-3.22
  • Solubility (experiment)N/A
  • LogS (predicted, ACD/Labs)(ph=7)-0.62
  • LogSw (predicted, AB/LogsW2.0)616.48
  • Sw (mg/ml) (predicted, ACD/Labs)128.93
  • No.of HBond Donors2
  • No.of HBond Acceptors6
  • No.of Rotatable Bonds15
  • TPSA58.2
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA cholinesterase inhibitor used in the management of myasthenia gravis.
  • Absorption_valueN/A
  • Absorption (description)Oral - poorly absorbed from the gastrointestinal tract.
  • Caco_2N/A
  • BioavailabilityN/A
  • Protein bindingN/A
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmPlasma and hepatic
  • Half lifeN/A
  • ExcretionN/A
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityLD50=150+/-44 mg/kg (orally in mice). Symptoms of overdose include muscle twitching, weakness and paralysis of voluntary muscles including the tongue, shoulders, neck and arms, blood pressure increase (with or without a slowing of heart rate), a sensation of internal trembling, severe anxiety, and panic. Death may occur rapidly if untreated.
  • LD50 (rat)N/A
  • LD50 (mouse)N/A